1. Introduction {#sec0001}
===============

Diabetes mellitus, especially type 2 diabetes, constitutes a global public health problem.[@bib0001] Most recent estimates show that, globally, approximately 415 million people live with diabetes, of which type 2 diabetes accounts for 90% of the diabetes population.[@bib0002] As the prevalence of diabetes continues to increase worldwide, particularly among middle- and low-income countries,[@bib0003], [@bib0004] the World Health Organization projects that the disease will become the seventh leading cause of death by 2030.[@bib0001] If not appropriately treated or managed, diabetes mellitus will have profound short- and long-term medical complications and, concomitantly, pose a significant economic burden to health care systems.[@bib0002]

Mounting evidence indicates that exercise produces significant physiological and health benefits[@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010] and prevents or delays the development of type 2 diabetes.[@bib0011], [@bib0012] Therefore, exercise is recommended for all individuals with diabetes as a part of the management of glycemic control and overall health.[@bib0013] In the past 2 decades, however, there has also been an increasing interest in discovering the health benefits of alternative, traditional Chinese exercises (TCEs) such as Tai Ji Quan, Qigong, and Ba Duan Jin.[@bib0014], [@bib0015], [@bib0016] Emerging randomized controlled trials (RCTs) and meta-analyses have reported beneficial effects of TCEs on glycemic profile in people with type 2 diabetes.[@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021]

Despite the potential benefits of TCEs for diabetic care, various design and methodologic weaknesses have consistently been identified across studies. The lack of scientific rigor observed in many RCTs has decreased the robustness of the findings, thus limiting broad generalizability. In addition, systematic reviews have often focused on single exercises, which may not reflect the collective health benefits of TCEs. To address these shortcomings, we extended previous individual reviews[@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021] to include recently published trials by conducting a systematic review and meta-analysis of the combined effects of 3 major and commonly studied TCEs (Tai Ji Quan, Qigong, and Ba Duan Jin) on the clinical biomarkers of glycemic control for adults with type 2 diabetes.

2. Methods {#sec0002}
==========

2.1. Protocol and registration {#sec0003}
------------------------------

This study was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.[@bib0022] The protocol was registered with the PROSPERO database (No. CRD42013006474).

2.2. Search strategy {#sec0004}
--------------------

Data sources used in this systematic review and meta-analysis included Cochrane Library, EMBASE, PubMed, Web of Science, EBSCO, and China National Knowledge Infrastructure. The electronic search used a mix of MeSH and free text terms to identify peer-reviewed articles on TCE-based RCTs that involved adults with type 2 diabetes. Accordingly, we used the search terms relevant to "randomized controlled trial", "type 2 diabetes", "traditional Chinese exercises", "glycemic control", and "hyperglycemia". A detailed description of search strategies is presented in the Appendix. The search was performed by 2 independent reviewers (CC, DZ) with restrictions imposed on the year of publication (from the origin of the database to September 2017) and language (English or Chinese), the studies that involved human participants, and published articles. No search was conducted on abstracts presented at international conferences.

2.3. Inclusion and exclusion criteria {#sec0005}
-------------------------------------

We considered a priori RCTs that examined the efficacy of any of the 3 *a priori* specified exercises (Tai Ji Quan, Qigong, or Ba Duan Jin) versus a control or other form of comparison (e.g., sham exercise, aerobic exercise, or routine treatment) on type 2 diabetes. The study population had to involve adults (≥18 years old) with type 2 diabetes, medically defined by a diagnosis of fasting blood glucose level of ≥7.0 mmol/L (≥126 mg/dL), a 2-h plasma glucose of ≥11.1 mmol/L (200 mg/dL), or a hemoglobin A1c (HbA1c) of ≥6.5%.[@bib0023] The study outcomes had to include biomarkers for diabetic risk factors, including HbA1c, fasting blood glucose, triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, 2-h plasma glucose, homeostasis model assessment, and fasting plasma glucose.

2.4. Data extraction and synthesis {#sec0006}
----------------------------------

Data extraction was performed independently by 2 reviewers (JZ, LC) in prespecified forms. The extraction included information on study population; total number of participants; intervention design; characterizes of intervention, including type, frequency, and duration; clinical outcome measures; and the results of the trial. In addition, descriptive statistics such as the number of study participants, trial duration, and mean and standard deviation of outcome measures at each assessment point (baseline, after the intervention) for the intervention and comparison groups were extracted. Information on the duration of interventions (≤3, \>3--\<12, and ≥12 months) was recorded. We also checked the research articles that met the eligibility criteria for duplicate reporting of the same data. Any conflicts or ambiguities in the reported methods or results occurring during the data extraction process were discussed with a third reviewer (XW) and resolved by consensus.

2.5. Outcomes {#sec0007}
-------------

The *a priori* primary outcomes of the study were HbA1c, recorded as percentage change, and fasting blood glucose, measured in the unit of mmol/L. Secondary outcomes included other biomarkers of triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, 2-h plasma glucose, and fasting plasma glucose, all measured in millimoles per liter. In addition, adverse events in the included studies, if any, were documented.

2.6. Risk of bias appraisal for individual studies {#sec0008}
--------------------------------------------------

We used the Cochrane Handbook for Systematic Reviews of Interventions[@bib0024] tool to conduct an overall assessment of risk of bias in systematic review (JZ, LC). For each RCT, we assessed sequence generation; allocation concealment; blinding of participants, staff, and outcome assessors; completeness of outcome data; and selective outcome reporting. The resulting evaluation was classified into 3 grades: low, unclear, and high risk of bias. Any discrepancies encountered during evaluation were discussed by inviting a third reviewer (XW) and resolved by consensus.

2.7. Data analysis {#sec0009}
------------------

If there were intent-to-treat data in our eligible studies, we preferred to use the intent-to-treat data. In each study, the difference in the study outcomes between the means of the exercise and comparison (control) groups at the end of the intervention was first calculated. We then computed the mean difference (MD) using the pooled data across the included studies via a random effect meta-analysis model. As an *a priori* analysis, we also analyzed the resulting data across 3 intervention durations, defined as short (≤3 months), medium (\>3--\<12 months), and long term (≥12 months). We presented the point estimates and their corresponding 95% confidence intervals (CIs). Tests of heterogeneity were performed using the Q statistic (with *p* \< 0.10 indicating statistically significant heterogeneity). For all other analyses, an *α* level of 0.05 was set *a priori* for statistical significance. We examined publication bias using forest plots and Egger\'s regression asymmetry test. To verify the reliability of our meta-analysis results, we conducted a sensitivity analysis by removing each study one by one to assess the consistency and quality of results. The meta-analyses were conducted using the Review Manager software (Version 5.2; The Nordic Cochrane Centre, Copenhagen, Denmark).

3. Results {#sec0010}
==========

3.1. Search results {#sec0011}
-------------------

The flow of records through the review is summarized in [Fig. 1](#fig0001){ref-type="fig"}. Our electronic searches resulted in 1117 potentially eligible reports or articles. We excluded 1005 of these based on the title, abstract, or repeated records. Of the 112 remaining articles, an additional 73 were excluded. The most common reasons for exclusion were a non-RCT design, unrelated outcomes, or non-type 2 diabetes. Eventually, 39 RCTs were deemed eligible for inclusion and synthesized for effectiveness.Fig. 1Flow chart of study selection. CNKI = China National Knowledge Infrastructure.Fig 1

3.2. Study characteristics {#sec0012}
--------------------------

All eligible studies were published between 2004 and 2017, and the studies varied in size, duration, and intervention type. A total of 2917 individuals participated in the 39 eligible trials that were subsequently meta-analyzed. Trial sample sizes ranged from 20 to 216 participants (median, 60; total, 2917). The duration of follow-up ranged from 1 to 12 months (median 4 months). With respect to TCE type, 11 involved a Tai Ji Quan intervention, 6 involved Qigong, and 22 involved Ba Duan Jin. The mean age of participants in the 39 studies (when this information was available) was 58.9 years and 48.8% of participants were women. Of the 39 eligible studies, 38 reported on HbA1c or fasting blood glucose levels (97.4%) and 25 had both main and secondary outcomes (64.1%). Results from 24 RCTs were analyzed using intent-to-treat data. The methodologic characteristics of the included studies are summarized in [Table 1](#tbl0001){ref-type="table"}.Table 1Characteristics of study design, intervention, and participants.Table 1Author, yearSample size, participant characteristic^a^InterventionExercise frequencyOutcomeStudy durationYu, 2004[@bib0025]40 subjects, mean age:\
G1 = 50.0 ± 5.8\
G2 = 49.0 ± 5.6G1: TJQ\
G2: routine treatmentOnce per dayFBG, HbA1c12 weeksWang et al., 2007[@bib0026]79 subjects, mean age:\
G1 = 57.8 ± 7.5\
G2 = 56.5 ± 6.9G1: BDJ + QG\
G2: routine treatmentOnce per dayTG, TC, HDL-C, HbA1c6 monthsLam et al., 2008[@bib0027]53 subjects, mean age:\
G1 = 63.2 ± 8.6\
G2 = 60.7 ± 12.2G1: TJQ\
G2: routine treatmentTwo 1-h classes per week for 3 months, then once per week for 3 monthsTG, TC, HbA1c6 monthsPan et al., 2008[@bib0028]48 subjects, mean age:\
G1 = 47.0 ± 7.0\
G2 = 45.0 ± 9.0G1: BDJ\
G2: routine treatmentOnce per day, 5 days per weekTC, HDL-C, FBG, HbA1c24 weeksTsang et al., 2008[@bib0029]38 subjects, mean age:\
G = 65.0 ± 7.8G1: TJQ\
G2: sham exerciseTwice per weekHbA1c16 weeksLin et al., 2009[@bib0030]94 subjects, mean age:\
G1 = 59.3 ± 5.2\
G2 = 59.8 ± 6.9\
G3 = 59.1 ± 6.3\
G4 = 55.3 ± 8.6G1: BDJ\
G2: BDJ + relaxation\
G3: relaxation\
G4: routine treatmentOnce per dayFBG, HbA1c2 months, 4 monthsLin et al., 2009[@bib0031]94 subjects, mean age:\
G1 = 59.3 ± 5.2\
G2 = 59.8 ± 6.9\
G3 = 59.1 ± 6.3\
G4 = 55.3 ± 8.6G1: BDJ\
G2: BDJ + relaxation\
G3: relaxation\
G4: routine treatmentOnce per dayFBG, HbA1c4 monthsWang et al., 2009[@bib0032]54 subjects, mean age:\
G1 = 49.2 ± 11.1\
G2 = 48.8 ± 10.5G1: TJQ\
G2: social dancing exercise5--7 times per weekTG, LDL-C, HDL-C, FBG, HbA1c6 monthsChen et al., 2010[@bib0033]104 subjects, mean age:\
G1 = 59.1 ± 6.2\
G2 = 57.4 ± 5.8G1: TJQ\
G2: the Hi-Low aerobic exercises3 times per weekTG, TC, HDL-C, FBG, HbA1c12 weeksHuang et al., 2011[@bib0034]60 subjects, mean age:\
G1 = 57.8 ± 7.5\
G2 = 56.5 ± 6.9G1: BDJ + QG\
G2: routine treatmentOnce per dayTG, TC, LDL-C, HDL-C, HbA1c, FPG6 monthsLiu et al., 2011[@bib0035]41 subjects, age:\
G = 41--71G1: QG\
G2: routine treatment3 times per weekTG, HDL-C, FBG, HbA1c, 2-h PG12 weeksZhou et al., 2011[@bib0036]122 subjects, mean age:\
G1 = 67.4 ± 9.2\
G2 = 68.1 ± 10.6G1: BDJ\
G2: aerobic exercisesG1: Twice per week\
G2: 3--5 times per weekTG, LDL-C, HDL-C, HbA1c3 monthsAhn et al., 2012[@bib0037]39 subjects, mean age:\
G1 = 66.0 ± 6.4\
G2 = 62.7 ± 7.5G1: QG\
G2: routine treatment1-h session twice per weekFBG, HbA1c12 weeksGuan et al., 2012[@bib0038]80 subjects, mean age:\
G1 = 59.2 ± 8.8\
G2 = 58.7 ± 8.3G1: BDJ\
G2: routine treatmentOnce per dayTG, FBG, HbA1c, 2-h PG4 monthsJi et al., 2012[@bib0039]62 subjects, mean age:\
G1 = 60.3 ± 7.2\
G2 = 60.2 ± 7.1G1: QG + diabetes education + routine treatmentG2: diabetes education + routine treatmentOnce per dayHbA1c, 2-h PG, FPG2 monthsLiu et al., 2012[@bib0040]69 subjects, mean age:\
G1 = 62.6 ± 5.9\
G2 = 65.6 ± 8.3G1: BDJ + community health education + routine treatmentG2: community health education + routine treatmentOnce per day, 3--5 days per weekHbA1c6 weeks, 12 weeksCheng et al., 2013[@bib0041]40 subjects, mean age:\
G1 = 65.5 ± 6.2\
G2 = 61.9 ± 7.0G1: QG\
G2: routine treatment1 h per day, 2--3 days per weekTG, TC, LDL-C, HDL-C, FBG, HbA1c, 2-h PG12 monthsLi et al., 2013[@bib0042]216 subjects, mean age:\
G1 = 50.4 ± 9.6\
G2 = 51.6 ± 7.8\
G3 = 54.2 ± 9.4\
G4 = 52.6 ± 8.3G1: BDJ\
G2: general aerobic exerciseG3: TJQG4: routine treatmentOnce per dayTC, HDL-C, HbA1c, FPG3 months, 9 monthsLin and Wei, 2013[@bib0043]38 subjects, mean age:\
G1 = 64.5 ± 11.5\
G2 = 60.8 ± 12.2G1: BDJ\
G2: routine treatmentOnce per dayTG, TC, LDL-C, HDL-C, HbA1c, FPG6 monthsLi and Wang, 2014[@bib0044]40 subjects, mean age:\
G1 = 53.6 ± 8.7\
G2 = 51.4 ± 9.2G1: BDJ\
G2: Routine treatmentOnce per dayHbA1c, FPG4 weeksLiu et al., 2014[@bib0045]40 subjects, mean age:\
G1 = 57.0 ± 7.0\
G2 = 55.0 ± 9.0G1: BDJ\
G2: routine treatmentOnce per day, 5 days per weekHbA1c6 monthsLu et al., 2014[@bib0046]120 subjects, mean age:\
G1 = 52.5 ± 1.7\
G2 = 48.0 ± 2.0G1: QG\
G2: routine treatmentOnce per dayHbA1c12 monthsMeng, 2014[@bib0047]200 subjects, mean age:\
G = 68.4 ± 3.2G1: TJQ\
G2: routine treatmentOnce per dayTG, TC, LDL-C, HDL-C, FBG, HbA1c3 monthsZhou, 2014[@bib0048]25 subjects, age:\
G1 = 51--72\
G2 = 58--80G1: BDJ + QG\
G2: routine treatmentOnce per dayFBG, HbA1c3 monthsCao et al., 2015[@bib0049]60 subjects, mean age:\
G1 = 58.9 ± 9.6\
G2 = 62.3 ± 9.9G1: BDJ\
G2: routine treatmentTwice per dayHbA1c12 weeksCao et al., 2015[@bib0050]60 subjects, mean age:\
G1 = 58.4 ± 9.1\
G2 = 60.8 ± 9.5G1: BDJ\
G2: routine treatmentTwice per dayHbA1c, FPG8 weeksLi et al., 2015[@bib0051]100 subjects, mean age:\
G1 = 62.9 ± 2.4\
G2 = 63.2 ± 2.8G1: TJQ\
G2: aerobic exerciseOnce per dayTG, TC, LDL-C, HDL-C, HbA1c, FPG6 monthsSun, 2015[@bib0052]65 subjects, mean age:\
G = 46.1 ± 11.8G1: BDJ + relaxation\
G2: routine treatmentTwice per weekHbA1c, 2-h PG, FPG6 monthsWang and Zhang, 2015[@bib0053]60 subjects, mean age:\
G1 = 61.7 ± 6.9\
G2 = 61.3 ± 8.4G1: BDJ\
G2: routine treatment5 times per weekTG, TC, LDL-C, HDL-C, FBG, HbA1c6 weeksWu and Wei, 2015[@bib0054]60 subjects, mean age:\
G1 = 63.9 ± 7.6\
G2 = 64.8 ± 5.8\
G3 = 65.3 ± 6.0G1: BDJ\
G2: walking\
G3: routine treatmentG1: 3 times per day, 5--7 days per week; G2: twice per day, 5--7 days per week; G3: daily routineHbA1c, FPG3 monthsZhang et al., 2015[@bib0055]108 subjects, mean age:\
G1 = 57.0 ± 2.4\
G2 = 55.4 ± 1.7\
G3 = 58.2 ± 1.0G1: BDJ\
G2: aerobic exercise\
G3: routine treatmentOnce per dayHbA1c, FPG100 daysHou, 2016[@bib0056]62 subjects, mean age:\
G1 = 58.8 ± 6.7\
G2 = 58.9 ± 6.4G1: BDJ\
G2: routine treatment5 days per weekTG, TC, HDL-C, HbA1c6 monthsWang et al., 2016[@bib0057]94 subjects, mean age:\
G1 = 63.3 ± 7.0\
G2 = 64.4 ± 6.3G1: TJQ + BDJ\
G2: routine treatmentOnce per dayTG, TC, LDL-C, HDL-C, HbA1c6 monthsYin et al., 2016[@bib0058]88 subjects, mean age:\
G1 = 56.4 ± 5.6\
G2 = 55.4 ± 9.1G1: BDJ\
G2: routine treatmentOnce per dayTG, LDL-C, HDL-C, FBG, HbA1c6 monthsGao, 2017[@bib0059]120 subjects, mean age:\
G1 = 61.2 ± 5.9\
G2 = 62.3 ± 6.6G1: QG\
G2: routine treatment5 days per weekHbA1c, FPG3 monthsOrr et al., 2006[@bib0060]35 subjects, mean age:\
G1 = 65.9 ± 7.4\
G2 = 64.9 ± 8.1G1: TJQ\
G2: sham exerciseTwice per weekFBG4 monthsXiao et al., 2011[@bib0061]48 subjects, mean age:\
G = 55.0 ± 4.1G1: TJQ\
G2: puerarin\
G3: TJQ + puerarin\
G4: routine treatmentOnce per dayFBG6 monthsPeng et al., 2015[@bib0062]141 subjectsG1: BDJ\
G2: routine treatmentOnce per dayFBG6 monthsZhang and Fu, 2008[@bib0063]20 subjects, mean age:\
G = 57.4 ± 6.2G1: TJQ\
G2: routine treatment1 h per day, 5 days per weekTG, TC, LDL-C, HDL-C, FPG14 weeks[^1][^2]

3.3. Risk of bias {#sec0013}
-----------------

The risk of bias assessment of all included studies is shown in [Fig. 2](#fig0002){ref-type="fig"}. All of the included studies described the process of random sequence generation. More than one-half of the studies (*n* = 22; 56.4%) were classified as having an unclear risk in the domains of allocation concealment. A high risk of bias was detected in the domain of blinding; none of the studies blinded participants and investigators and only 6 (15.4%) of them were shown to blind their outcome assessment. A low risk of incomplete outcome data bias was observed in all of the studies (*n* = 39; 100%). With respect to selective outcome reporting bias, 36 (92.3%) studies were graded as low risk and the remaining were graded as unclear risk (*n* = 3; 7.7%).Fig. 2Risk of bias assessment.Fig 2

3.4. Effects of TCEs on primary outcomes {#sec0014}
----------------------------------------

The results showed that, overall, compared with a control or comparison group, TCEs significantly lowered the percentage of HbA1c (MD = −0.67%; 95%CI: −0.86% to −0.48%; *p* \< 0.00001) and fasting blood glucose (MD = −0.66 mmol/L; 95%CI: −0.95 to −0.37 mmol/L; *p* \< 0.0001; [Table 2](#tbl0002){ref-type="table"}; [Figs. 3](#fig0003){ref-type="fig"} and [4](#fig0004){ref-type="fig"}). The effect on HbA1c was most pronounced in both short-term (MD = −0.51%; 95%CI: −0.74% to −0.28%; *p* \< 0.0001) and medium-term durations of study (MD = −0.78%; 95%CI: −1.06% to −0.50%; *p* \< 0.00001), with a marginal effect in the studies with a long-term duration of study (MD = −1.00%; 95%CI: −2.04% to 0.03%; *p* = 0.06). In contrast, TCEs showed a significant effect on fasting blood glucose in studies conducted with medium-term durations (MD = −0.87 mmol/L; 95%CI: −1.38 to −0.35 mmol/L; *p* = 0.001) and long-term durations (MD = −0.55 mmol/L; 95%CI: −0.70 to −0.40 mmol/L; *p* \< 0.00001), but not in the short-term duration studies (MD = −0.42 mmol/L; 95%CI: −0.99 to 0.16 mmol/L; *p* = 0.16). There is, in general, significant heterogeneity shown in these point estimates ([Table 2](#tbl0002){ref-type="table"}).Table 2Summary of the meta-analysis results by study length.Table 2OutcomeNumber of RCTsNo. of participantsEffect estimate (95%CI)Heterogeneity*p*Main outcomes HbA1c (%)35[@bib0025], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030], [@bib0031], [@bib0032], [@bib0033], [@bib0034], [@bib0035], [@bib0036], [@bib0037], [@bib0038], [@bib0039], [@bib0040], [@bib0041], [@bib0042], [@bib0043], [@bib0044], [@bib0045], [@bib0046], [@bib0047], [@bib0048], [@bib0049], [@bib0050], [@bib0051], [@bib0052], [@bib0053], [@bib0054], [@bib0055], [@bib0056], [@bib0057], [@bib0058], [@bib0059]2940−0.67 (−0.86 to −0.48)\<0.00001\<0.00001  Short term17[@bib0025], [@bib0030][@bib0033][@bib0035], [@bib0036], [@bib0037][@bib0039], [@bib0040][@bib0042], [@bib0044][@bib0047], [@bib0048], [@bib0049], [@bib0050][@bib0053], [@bib0054][@bib0059]1402−0.51 (−0.74 to −0.28)\<0.00001\<0.0001  Medium term18[@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030], [@bib0031], [@bib0032]^,^[@bib0034], [@bib0038]^,^[@bib0042], [@bib0043]^,^[@bib0045], [@bib0051]^,^[@bib0052]^,^[@bib0055], [@bib0056], [@bib0057], [@bib0058]1378−0.78 (−1.06 to −0.50)\<0.00001\<0.00001  Long term2[@bib0041], [@bib0046]160−1.00 (−2.04 to 0.03)0.020.06 FBG (mmol/L)18[@bib0025], [@bib0028]^,^[@bib0030], [@bib0031], [@bib0032], [@bib0033]^,^[@bib0035], [@bib0037]^,^[@bib0038], [@bib0041]^,^[@bib0046], [@bib0047], [@bib0048]^,^[@bib0053], [@bib0058]^,^[@bib0060], [@bib0061], [@bib0062]1433−0.66 (−0.95 to −0.37)\<0.00001\<0.0001  Short term8[@bib0025], [@bib0030]^,^[@bib0033], [@bib0035]^,^[@bib0037], [@bib0047]^,^[@bib0048], [@bib0053]593−0.42 (−0.99 to 0.16)\<0.00010.16  Medium term9[@bib0028]^,^[@bib0030], [@bib0031], [@bib0032]^,^[@bib0038], [@bib0058]^,^[@bib0060], [@bib0061]^,^[@bib0062]680−0.87 (−1.38 to −0.35)0.0010.001  Long term2[@bib0041], [@bib0046]160−0.55 (−0.70 to −0.40)0.70\<0.00001Secondary outcomes TG (mmol/L)17[@bib0026], [@bib0027]^,^[@bib0032], [@bib0033], [@bib0034], [@bib0035], [@bib0036]^,^[@bib0038], [@bib0041]^,^[@bib0043], [@bib0047]^,^[@bib0051], [@bib0053]^,^[@bib0056], [@bib0057], [@bib0058]^,^[@bib0063]1283−0.49 (−0.71 to −0.26)\<0.00001\<0.0001  Short term5[@bib0033], [@bib0035]^,^[@bib0036], [@bib0047]^,^[@bib0053]517−0.49 (−0.86 to −0.12)0.0050.01  Medium term11[@bib0026], [@bib0027]^,^[@bib0032], [@bib0034]^,^[@bib0038], [@bib0043]^,^[@bib0051]^,^[@bib0056], [@bib0057], [@bib0058]^,^[@bib0063]726−0.47 (−0.77 to −0.16)\<0.000010.003 TC (mmol/L)14[@bib0026], [@bib0027], [@bib0028]^,^[@bib0033], [@bib0034]^,^[@bib0041], [@bib0042], [@bib0043]^,^[@bib0047], [@bib0051]^,^[@bib0053], [@bib0056]^,^[@bib0057], [@bib0063]1303−0.41 (−0.57 to −0.25)0.006\<0.00001  Short term4[@bib0033], [@bib0042]^,^[@bib0047], [@bib0053]570−0.36 (−0.65 to −0.07)0.050.01  Medium term10[@bib0026], [@bib0027], [@bib0028]^,^[@bib0034], [@bib0042]^,^[@bib0043], [@bib0051]^,^[@bib0056], [@bib0057]^,^[@bib0063]693−0.47 (−0.66 to −0.28)0.04\<0.00001 LDL-C (mmol/L)11[@bib0032], [@bib0034]^,^[@bib0036], [@bib0041]^,^[@bib0043], [@bib0047]^,^[@bib0051], [@bib0053]^,^[@bib0057], [@bib0058]^,^[@bib0063]876−0.23 (−0.41 −0.06)0.0010.008  Short term3[@bib0036], [@bib0047]^,^[@bib0053]382−0.36 (−0.51 to −0.20)0.46\<0.00001  Medium term7[@bib0032], [@bib0034]^,^[@bib0043], [@bib0051]^,^[@bib0057], [@bib0058]^,^[@bib0063]454−0.14 (−0.41 to 0.13)0.00020.31 HDL-C (mmol/L)17[@bib0026], [@bib0028]^,^[@bib0032], [@bib0033], [@bib0034], [@bib0035], [@bib0036]^,^[@bib0041], [@bib0042], [@bib0043]^,^[@bib0047], [@bib0051]^,^[@bib0053]^,^[@bib0056], [@bib0057], [@bib0058]^,^[@bib0063]16320.14 (0.07 to 0.21)\<0.000010.0002  Short term6[@bib0033], [@bib0035]^,^[@bib0036], [@bib0042]^,^[@bib0047], [@bib0053]7330.06 (−0.02 to 0.14)0.170.15  Medium term11[@bib0026], [@bib0028]^,^[@bib0032], [@bib0034]^,^[@bib0042], [@bib0043]^,^[@bib0051]^,^[@bib0056], [@bib0057], [@bib0058]^,^[@bib0063]8590.13 (0.05 to 0.21)0.00030.002 2-h PG (mmol/L)5[@bib0035], [@bib0038]^,^[@bib0039], [@bib0041]^,^[@bib0052]288−2.14 (−2.79 to −1.49)0.74\<0.00001  Short term2[@bib0035], [@bib0039]103−2.45 (−3.66 to −1.25)0.43\<0.0001  Medium term2[@bib0038], [@bib0052]145−2.21 (−3.07 to −1.34)0.99\<0.00001 FPG (mmol/L)12[@bib0034], [@bib0039]^,^[@bib0042], [@bib0043], [@bib0044]^,^[@bib0050], [@bib0051], [@bib0052]^,^[@bib0054], [@bib0055]^,^[@bib0059], [@bib0063]1142−0.85 (−1.31 to −0.39)\<0.00010.0003  Short term6[@bib0039], [@bib0042]^,^[@bib0044], [@bib0050]^,^[@bib0054], [@bib0059]558−0.71 (−1.15 to −0.26)0.060.002  Medium term7[@bib0034], [@bib0042]^,^[@bib0043], [@bib0051]^,^[@bib0052], [@bib0055]^,^[@bib0063]584−1.08 (−2.01 to −0.14)\<0.00010.02[^3]Fig. 3Forest plot on hemoglobin A1c outcome in randomized, controlled trials with short-, medium-, and long-term durations. Forest plot showing the mean difference in change in hemoglobin A1c between TCEs and control/comparison groups across the studies that were conducted in short-, medium-, and long-term durations. CI = confidence interval; IV = inverse variance; SD = standard deviation; TCE = traditional Chinese exercise.Fig 3Fig. 4Forest plot on fasting blood glucose outcome in randomized, controlled trials with short-, medium-, and long-term durations. Forest plot showing the mean difference in change in fasting blood glucose between TCEs and control/comparison groups across the studies that were conducted in short-, medium-, and long-term durations. CI = confidence interval; IV = inverse variance; SD = standard deviation; TCE = traditional Chinese exercise.Fig 4

3.5. Effects of TCEs on secondary outcomes {#sec0015}
------------------------------------------

As shown in [Table 2](#tbl0002){ref-type="table"}, TCEs were shown to have a significant effect on all secondary outcomes. With respect to responses to different intervention lengths, only 2 nonsignificant results were observed in the outcomes of low-density lipoprotein cholesterol (MD = −0.14; 95%CI: −0.41 to 0.13; *p* = 0.31) for the studies that had a medium-term duration and high-density lipoprotein cholesterol (MD = 0.06; 95%CI: −0.02 to 0.14; *p* = 0.15) for those with a short-term duration.

3.6. Adverse events {#sec0016}
-------------------

None of the studied reported adverse events. Therefore, this information could not be retrieved from the RCTs analyzed.

3.7. Sensitivity analysis {#sec0017}
-------------------------

By removing single studies, the sensitivity analyses showed no noticeable changes in the statistical significance of all primary or secondary outcomes.

3.8. Publication bias {#sec0018}
---------------------

As shown from the Egger\'s asymmetry tests, there was little indication of publication bias on the primary outcomes (*p* = 0.147 for HbA1c; *p* = 0.418 for fasting blood glucose, respectively). Among secondary outcomes, the Egger\'s test showed publication bias only on high-density lipoprotein cholesterol (*p* = 0.041).

4. Discussion {#sec0019}
=============

Our study is the first to conduct a systematic review and meta-analysis of pooled effects among the 3 most common TCEs on clinical biomarkers of diabetes control. In our meta-analysis of the pooled results from 39 RCTs that included 2917 individuals with type 2 diabetes, we found that, on average, compared with a control/comparison group, combined TCE interventions reduced HbA1c (0.67% lower) and fasting blood glucose (0.66 mmol/L lower). In addition, we found good evidence that TCE interventions lowered the level of HbA1c with interventions that were implemented in both short-term (i.e., ≤3 months) and medium-term (i.e., \>3--\<12 months) durations and fasting blood glucose on medium-term (i.e., \>3--\<12 months) and long-term (≥12 months) durations. TCEs also had a positive effect in improving secondary study biomarkers, including triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and 2-h plasma glucose. In general, there was high heterogeneity observed in these estimates across interventions of different lengths.

Results from our meta-analyses are generally congruent with previous systematic reviews and meta-analysis reports of single TCEs on glycemic responses in people with type 2 diabetes.[@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021] For example, positive impacts of Ba Duan Jin plus conventional therapy and Qigong interventions on HbA1c, fasting blood glucose, and other biomarkers have been reported.[@bib0018], [@bib0019] The impact of Tai Ji Quan, however, was less consistent, with some positive results occurring for HbA1c and fasting blood glucose when comparing Tai Ji Quan with either a control or other experimental conditions.[@bib0017], [@bib0021] By pooling available TCE intervention data published between 2004 and 2017, we were able to show a consistent positive effect of combined TCE interventions on glycemic biomarkers that are highly relevant to diabetes control and management.

Our analyses by studies of different intervention durations show that TCE interventions lasting \>3--\<12 months generally produced consistent results on reductions in both HbA1c and fasting blood glucose. These results could possibly be explained by the slow and meditative nature of exercises inherent in many of the TCE modalities being evaluated (e.g., Tai Ji Quan, Qigong, and Ba Duan Jin).[@bib0014], [@bib0015], [@bib0016] We found no long-term (i.e., ≥12 months) practice effect of TCEs on HbA1c. Although short-term interventions (i.e., ≤3 months) were shown to decrease the level of HbA1c, they did not bring about a change in fasting blood glucose, suggesting that a longer training period may be necessary to elicit a clinical reduction. Although the exact mechanism for the inconsistent findings remains unknown, factors such as low intervention dose or intensity, nonblinding in outcome assessment, or poor quality in fidelity control may have played a role. Future studies designed with high scientific rigor are needed to better understand the impact of short- and long-term TCE training on glycemic control.

4.1. Study limitations {#sec0020}
----------------------

The study has some notable limitations. Among the RCTs included, there was great heterogeneity with respect to intervention intensity, duration, and frequency that may have contributed to unwanted heterogeneity and, consequently, may have further influenced the study outcomes. Even with our categorization of intervention durations (i.e., short, medium, and long term), the relatively small number of studies included in each category did not allow us to effectively account for the heterogeneity underlying the different studies in our random effect models. Therefore, the extent to which exercise dose or duration impacts exercise-induced improvement of glycemic control remains to be elucidated. Moreover, as previously reported,[@bib0017], [@bib0020] the methodologic quality of the RCTs included in our review was generally low, with poor quality control over the lack of allocation concealment mechanism and blinding, which often introduces selection bias in the design and execution of a clinical trial.

4.2. Practical implications {#sec0021}
---------------------------

One of the notable strengths of TCEs is that they can be implemented without the need for equipment, large exercise spaces, or intensive safety monitoring and supervision that are often required in other exercise interventions (e.g., resistance training, aerobic exercise). Thus, TCEs hold great potential for scaling up dissemination efforts across communities for diabetic care and diabetes prevention. Although TCEs are highly promising from a public health viewpoint, we still do not know what constitutes an appropriate exercise dose to achieve optimal benefits in glycemic control. Similarly, little is known regarding whether the duration of exercise programs (short or long term) is associated with producing a uniform effect on glycemic biomarkers, including HAb1c and fasting blood glucose. Increasing our knowledge in these areas will be of high importance in developing clinical guidelines for diabetic care and management.

5. Conclusion {#sec0022}
=============

TCEs, such as Tai Ji Quan, Ba Duan Jin, and Qigong, are shown to be effective for type 2 diabetic individuals in lowering their risk of metabolic complications, compared with either a control or other form of care. Although our results add to the growing body of evidence supporting the use of TCEs to optimize reductions in markers of glycemic control, further studies to better understand the optimal dose and duration of exposure to TCE interventions are warranted.
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[^1]: Notes: ^a^The unit of age is year. Data presented as mean ± SD for the "mean age".

[^2]: Abbreviations: 2-h PG = 2-h plasma glucose; BDJ = Ba Duan Jin; FBG = fasting blood glucose; FPG = fasting plasma glucose; G = group; HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; QG = Qigong; TC = total cholesterol; TG = triglyceride; TJQ = Tai Ji Quan.

[^3]: Abbreviations: 2-h PG = 2-h plasma glucose; CI = confidence interval; FBG = fasting blood glucose; FPG = fasting plasma glucose; HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; RCT = randomized controlled trial; TC = total cholesterol; TG = triglycerides.
